Selective inhibitors of COX-2 - Are they safe for the stomach?

Scandinavian Journal of Gastroenterology

Volumn 35, Issue 11, 2000, Pages 1121-1124

  Giercksky, K E ^a   Haglund, U ^a   Rask Madsen, J ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

DIGESTIVE SYSTEM INJURY; DISEASE ASSOCIATION; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STOMACH EPITHELIUM;

EID: 0033636411     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655200750056565     Document Type: Review

References (27)

1. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
2. Temporal and pharmacological division of fibroblast cyclooxygenase expersison into transcriptional and translational phases
3. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
4. The discovery and function of COX-2
5. Cyclooxygenase in biology and disease
6. The risks and costs of upper gastrointestinal disease attributable on NSAIDs
7. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models
8. Actions and toxic effects of the nonsteroidal anti-inflammatory drugs
9. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy
10. Prevention of NSAID-induced gastric ulcer with misoprostal: Multicentre, doubleblind placebo-controlled trail
11. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs
12. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
13. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study
14. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
15. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial
16. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
17. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
18. Comparison of the effect of 'rofecoxib' (a cyclo-oxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis - A randomized, double-blind; placebo-controlled trial
19. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal (UGI) events in osteoarthritis (OA) and rheumatoid arthritis (RA) patients as compared to NSAIDs
20. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
21. Effects of celcoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
22. Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal antiinflammatory drug-related nephrotoxicity
23. Immunolocalizafion of cyclooxygenase-2 in the macula densa of human elderly
24. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital due to inflammatory bowel disease
25. Upper gastrointestinal tolerability of celcoxib, a COX-2 specific inhibitor, compared to naproxen and placebo
26. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention
27. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis